nep-dcm New Economics Papers
on Discrete Choice Models
Issue of 2011‒09‒16
one paper chosen by
Philip Yu
Hong Kong University

  1. The Flexible Substitution Logit: Uncovering Category Expansion and Share Impacts of Marketing Instruments By Qiang Liu; Thomas J. Steenburgh; Sachin Gupta

  1. By: Qiang Liu (The Krannert School of Management, Purdue University); Thomas J. Steenburgh (Harvard Business School, Marketing Unit); Sachin Gupta (The Johnson Graduate School of Management, Cornell University)
    Abstract: Different instruments are relevant for different marketing objectives (category demand expansion or market share stealing). To help brand managers make informed marketing mix decisions, it is essential that marketing mix models appropriately measure the different effects of marketing instruments. Discrete choice models that have been applied to this problem might not be adequate because they possess the Invariant Proportion of Substitution (IPS) property, which imposes counter-intuitive restrictions on individual choice behavior. Indeed our empirical application to prescription writing choices of physicians in the hyperlipidemia category shows this to be the case. We find that three commonly used models that all suffer from the IPS restriction - the homogeneous logit model, the nested logit model, and the random coefficient logit model - lead to counter-intuitive estimates of the sources of demand gains due to increased marketing investments in Direct-to-Consumer Advertising (DTCA), detailing, and Meetings and Events (M&E). We then propose an alternative choice model specification that relaxes the IPS property - the so-called "flexible substitution" logit (FSL) model. The (random coefficient) FSL model predicts that sales gains from DTCA and M&E come primarily from the non-drug treatment (87.4% and 70.2% respectively), whereas gains from detailing come at the expense of competing drugs (84%). By contrast, the random coefficient logit model predicts that gains from DTCA, M&E and detailing all would come largely from competing drugs.
    Date: 2011–08

This nep-dcm issue is ©2011 by Philip Yu. It is provided as is without any express or implied warranty. It may be freely redistributed in whole or in part for any purpose. If distributed in part, please include this notice.
General information on the NEP project can be found at For comments please write to the director of NEP, Marco Novarese at <>. Put “NEP” in the subject, otherwise your mail may be rejected.
NEP’s infrastructure is sponsored by the School of Economics and Finance of Massey University in New Zealand.